We have examined the possible mechanisms of resistance to the epidermal growth factor receptor (EGFR) inhibitors in tumor cells with variable levels of EGFR. ZD1839 (Iressa) is a small-molecular-weight, ATP-mimetic that specifically inhibits the EGFR tyrosine kinase. A431 cell growth was markedly inhibited by ZD1839 (IC 50 p0.1 lm) whereas the MDA-468 cells were relatively resistant (IC 50 >2 lm). Low doses of ZD1839 delayed cell cycle progression and induced apoptosis in A431 cells but not in MDA-468 cells. In both cell lines, 0.1 lm ZD1839 eliminated EGFR phosphorylation. However, the basal activity of the phosphatidylinositol-3 kinase (PI3 K) target Akt was eliminated in A431 but not in MDA-468 cells, implying that their Akt activity is independent of EGFR signals. A431 cells express PTEN/MMAC1/TEP, a phosphatase that can dephosphorylate position D3 of phosphatidylinositol-3,4,5 trisphosphate, the site that recruits the plecstrin-homology domain of Akt to the cell membrane. On the contrary, MDA-468 cells lack the phosphatase and tensin homolog (PTEN), potentially setting Akt activity at a high threshold that is unresponsive to EGFR inhibition alone. Therefore, we reintroduced (PTEN) by retroviral infection in MDA-468 cells. In MDA-468/PTEN but not in vector controls, treatment with ZD1839 inhibited P-Akt levels, induced relocalization of the Forkhead factor FKHRL1 to the cell nucleus, and increased FKHRL1-dependent transcriptional activity. ZD1839 induced a greater degree of apoptosis and cell cycle delay in PTEN-reconstituted than in control cells. These data suggest that loss of PTEN, by permitting a high level of Akt activity independent of receptor tyrosine kinase inputs, can temporally dissociate the inhibition of the EGFR with that of Akt induced by EGFR inhibitors. Thus, in EGFR-expressing tumor cells with concomitant amplification(s) of PI3K-Akt signaling, combined blockade of the EGFR tyrosine kinase and Akt should be considered as a therapeutic approach.
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Introduction
The epidermal growth factor receptor (EGFR, HER1, erbB1) is a 170-kDa protein composed of an extracellular ligand-binding domain, a short transmembrane domain, and an intracellular domain with intrinsic tyrosine kinase activity. Overexpression and/or hyperactivity of the EGFR has been shown to play a causal role in the progression of several epithelial neoplasms (reviewed in Prenzel et al., 2001; Yarden and Sliwkowski, 2001 ). The EGFR is activated by binding of ligand(s) to its extracellular domain which leads to receptor homodimerization or heterodimerization with any of the other three members of this family of transmembrane tyrosine kinases: HER2 (erbB2), HER3 (erbB3), and HER4 (erbB4). This results in binding of ATP to the receptor's catalytic site, activation of the receptor's tyrosine kinase, and autophosphorylation on C-terminal tyrosine residues, which, in turn, recruit several cytoplasmic signal transducers. These effector molecules include PLC-g1, Ras-MEK-MAPK, phosphatidylinositol-3 kinase (PI3K) and its target Akt, p70S6 kinase, Src, and STATs, among others (Olayioye et al., 2000; Yarden and Sliwkowski, 2001) .
The oncogenic potential of the EGFR and its high level of expression in tumor tissues provides a rationale for targeting this oncoprotein with novel molecular therapeutics. Indeed, anti-EGFR molecules inhibit the progression of EGFR-dependent preclinical models and have recently demonstrated clinical efficacy against several human carcinomas (reviewed in Arteaga, 2001 ). The antitumor effect of these inhibitors requires the subversion of key postreceptor signaling pathways and cell cycle/apoptosis regulatory molecules that mediate the transforming effects of the EGFR network. Inactivation of constitutively active MAPK and the serine/ threonine kinase Akt, a target of PI3K, have been reported in EGFR-dependent tumor cells treated with EGFR inhibitors (Fan et al., 1997; Busse et al., 2000; Lenferink et al., 2000; Albanell et al., 2001; Nelson and Fry, 2001 ). In addition, inhibition of the homologous tyrosine kinase HER2 in tumor cells results in inhibition of PI3K and Akt Hermanto et al., 2001; Lenferink et al., 2001; Moulder et al., 2001; Yakes et al., 2002) . The antitumor effect of HER2 inhibitors has been shown to require the subversion of Akt function .
EGFR-mediated activation of Akt requires the activation of PI3K. This can occur via dimerization of EGFR with HER3, which is able to couple to PI3K directly (Fedi et al., 1994) , or by interaction of the receptor with the intracellular adaptor Gab1 (Rodrigues et al., 2000) . Upon activation, PI3K converts phosphatidylinositol-4,5 bisphosphate (PI4,5P2) to phosphatidylinositol-3,4,5 trisphosphate (PI3,4,5P3); this lipid recruits the plecstrin-homology (PH) domain of Akt to the plasma membrane where its serine/threonine kinase is activated by phosphoinositide-dependent kinase 1 (PDK1)-and PDK2-mediated phosphorylation (Chan et al., 1999) . Active Akt phosphorylates a number of substrates involved in apoptosis, cell cycle regulation, protein synthesis, and glycogen metabolism, which include the Bcl-2 family member Bad, Forkhead transcription factors, caspase-9, IkB kinase, MDM2, GSK-3b, p21
Waf1
, p27 Kip1 , mTOR, and nitric oxide synthase (Datta et al., 1999; Zhou et al., 2001a, b; Shin et al., 2002) . Via phosphorylation, Akt functionally inactivates these proapoptotic and cell-cycle-regulatory molecules, thus enhancing tumor cell survival and proliferation. In human tumors, Akt activity has been shown to be upregulated by several alterations which include PI3K isoform gene amplification, activating mutations of p85, Akt gene amplification and overexpression, as well as loss of function of the phosphatase and tensin homolog (PTEN) phosphatase (Vivanco and Sawyers, 2002) . PTEN dephosphorylates the D3 position of membrane PI3,4,5P3 providing negative regulation of PI3K and Akt activities (Cantley and Neel, 1999; Simpson and Parsons, 2001 ). Mutations and/or deletions in PTEN occur with variable frequency in advanced cancers including glioblastoma multiforme, melanoma, endometrial, breast, ovarian, renal cell, thyroid, and a small subset of small-cell and nonsmallcell lung cancers (NSCLC) (Ali et al., 1999; Vivanco and Sawyers, 2002) . Reconstitution of PTEN expression in PTEN-null cells has been shown to repress Akt and inhibit tumor growth via induction of apoptosis or repression of cell proliferation (Li and Sun, 1998; Lu et al., 1999; Sun et al., 1999) .
The data summarized above suggest that inhibition of Akt is required for the antitumor effect of EGFR inhibitors. Hence, we speculate that EGFR-overexpressing tumor cells with coexisting amplification of the PI3K-Akt pathway might harbor Akt activity at a high threshold and, therefore, not respond to EGFR tyrosine kinase inhibitors alone. We have examined this hypothesis in MDA-468 human breast cancer cells which overexpress EGFR and carry a deletion and frame-shift mutation at codon 70 of the PTEN protein as well as in PTEN-expressing and PTEN-null NSCLC cell lines.
Results

EGFR-overexpressing cancer cells with mutant PTEN are less sensitive to ZD1839
We initially examined the effects of ZD1839 (Iressa) on A431 and MDA-468 human cancer cells. ZD1839 is an ATP-competitive inhibitor of the EGFR catalytic activity; it inhibits the EGFR tyrosine kinase (isolated from A431 cell membranes) in vitro with an IC 50 of 0.033 mm (Wakeling et al., 2002) . A431 and MDA-468 cells exhibit EGFR gene amplification and secrete TGFa, thus expressing autoactivated EGFR in the absence of exogenous ligands (Ennis et al., 1989; Van de Vijver et al., 1991) . ZD1839 inhibited the growth of (wild-type (WT) PTEN) A431 cells with an approximate IC 50 of 0.1 mm whereas the PTEN-null MDA-468 cells were relatively resistant to concentrations as high as 1 mm (Figure 1a ). Similar data were obtained with the humanized anti-EGFR IgG 2 C225 (Goldstein et al., 1995) and the EGFR tyrosine kinase inhibitor OSI-774 (Moyer et al., 1997) (data not shown). As measured by TUNEL and flow cytometry of labeled nuclei, ZD1839 treatment resulted in apoptosis and cell cycle delay in A431 cells. These effects were not seen in MDA-468 cells (Figure 1b, c) . To test the integrity of the PI3K pathway, we used LY294002, a specific inhibitor of the p110 catalytic subunit of PI3K (Vlahos et al., 1994) . In both cell lines, LY294402 induced apoptosis and cell cycle arrest; the latter was more marked in the PTEN-null MDA-468 than in A431 cells (Figure 1b, c) .
ZD1839 inhibits EGFR phosphorylation and coupling to p85 in A431 and MDA-468 cells Consistent with its EGFR specificity, sub-micromolar concentrations of ZD1839 induced a similar degree of inhibition of basal EGFR tyrosine phosphorylation in both A431 and MDA-468 cells without a change in receptor protein levels ( Figure 2a) . As a result of the published effect of EGFR inhibitors on PI3K/Akt signaling and the potent ability of HER3 to couple to PI3K directly (Fedi et al., 1994) , we examined the effect of ZD1839 on this signaling pathway and on EGFR/ HER3 interactions. In A431 cells, treatment with ZD1839 markedly reduced the constitutive association of EGFR with HER3 and with the regulatory subunit of PI3K, p85a. MDA-468 cell lysates exhibited low levels of HER3 by immunoblot (not shown). Compatible with this observation, p85a, but not HER3, was detectable in EGFR precipitates from these cells. ZD1839 markedly reduced the basal coupling of EGFR with p85 in MDA-468 cells (Figure 2a ). Interestingly, Akt activation state as assessed by immunoblot analysis using antibodies specific to S473 P-Akt was reduced in A431 but not in MDA-468 cells without a change in total Akt protein levels following treatment with ZD839 ( Figure 2b ). LY294002 induced almost complete elimination of PAkt levels in both cell lines (Figure 2b ), indicating that P-Akt phosphorylation is dependent on PI3K activity in MDA-468 cells. These results also imply that, in the PTEN-null MDA-468 cells, Akt activity is independent of EGFR autocrine signaling.
Reconstitution of PTEN restores ZD1839-mediated inhibition of Akt
To restore PTEN expression in MDA-468 cells, we introduced full-length PTEN into the pBMN-IRES-EGFP retroviral expression vector (Grignani et al., 1998) . In this vector, PTEN was subcloned immediately upstream an internal ribosomal entry sequence ( 1-1 mm ZD1839 (in IMEM/1% FCS) and harvested after 24 h. Whole-cell lysates were prepared and 1 mg of total protein precipitated with an EGFR antibody. Immune complexes were next divided into four equal parts, each separated by 8% SDS-PAGE, and finally subjected to Immunoblot analysis for EGFR, P-Tyr, HER3, and p85. (b) Cells were treated with ZD1839 or LY294002 at the indicated concentrations and harvested after 24 h; 60 mg of total cell lysates were separated by 10% SDS-PAGE followed by Immunoblot analysis for S473 P-Akt and total Akt To examine Akt function in response to ZD1839, we utilized a hemaglutinin (HA)-tagged FKHLR1 expression vector. FKHRL1 is a Forkhead transcription factor that has been shown to induce the transcription of cell-death-related genes (Kops and Burgering, 1999) . Upon phosphorylation by Akt, FKHRL1 translocates from the nucleus to the cytoplasm where 14-3-3 proteins sequester it and prevent its function (Datta et al., 1999; Shin et al., 2001) . In A431, MDA-468, MDA-468/ vector, and MDA-468/PTEN cells transiently transfected FKHRL1 localized predominantly in the cytoplasm (Figure 5a , column 1 of each panel), consistent with the constitutive Akt activity in these cells. Treatment with ZD1839 resulted in nuclear localization of FKHRL1 in A431 but not in PTEN-negative parental and vector control MDA-468 cells. However, blockade of the EGFR kinase with ZD1839 in MDA-468/PTEN cells resulted in nuclear distribution of FKHRL1 (Figure 5a , bottom row of right panel).
We next asked whether Forkhead (FHRE)-dependent transcriptional activity, as a function of inhibition of Akt, had been restored in the PTEN-transduced cells. Cells were transiently transfected with an FHRE-Luc vector in which a Forkhead response element is linked to a luciferase reporter gene. FHRE contains the binding site of the FasL promoter. FKHRL1 binds this site and enhances transcription of the FasL gene . Treatment with ZD1839 did not induce Forkhead transcriptional activity in parental and vector-transfected MDA-468 cells. However, consistent with its ability to inhibit Akt, treatment with 1 mm ZD1839 for 24 h increased FHRE-dependent luciferase expression in both A431 and MDA-468/PTEN cells (Figure 5b ). With the FKHRL1 localization data (above), these data further support that the ability of ZD1839 to inhibit Akt function had been restored by reintroduction of PTEN.
Proliferation and survival of MDA-468/PTEN cells are inhibited by EGFR inhibitors
We finally examined if re-expression of PTEN restored sensitivity of MDA-468 to EGFR kinase inhibitors. MDA-468/PTEN cells were markedly more sensitive to ZD1839 compared to MDA-468/vector cells (IC 50 approximately 0.1 vs >1 mm, respectively) (Figure 6a ). In addition, a 72-h incubation with ZD1839 resulted in marked dose-dependent cell death in MDA-468/PTEN cells, which was much less obvious in the PTENnegative controls (Figure 6b) . Furthermore, the inhibition of cell cycle progression, as measured by flow cytometry of propidium-iodide-labeled cell nuclei, was modestly greater in PTEN-reconstituted than in MDA-468/vector cells (Figure 6c) . Finally, the EGFR inhibitors C225 and OSI-774 also induced a greater degree of apoptosis in MDA-468/PTEN than in control cells (Figure 6d ), implying that re-expression of PTEN had mainly restored or enhanced the ability of EGFR inhibitors to induce tumor cell apoptosis.
PTEN-null NSCLC cells are less sensitive to ZD1839
To determine if this differential sensitivity to EGFR inhibitors as a function of PTEN status was not limited to A431 and MDA-468 cells, we performed similar experiments in H1355 and H157 NSCLC lines. H1355 cells have WT PTEN (Kohno et al., 1998) . The H157 cell line lacks PTEN protein and exhibits a nonsense mutation of the PTEN gene (Forgacs et al., 1998) . Both cell lines contain a mutation of K-ras (Brognard et al., 2001) . They exhibited equal levels of cell surface EGFR by flow cytometry of cells labeled with an EGFR antibody against the receptor's extracellular domain 
Discussion
In this report, we have examined the potential mechanisms of resistance to EGFR inhibitors in EGFRoverexpressing human carcinoma cells. Studies in transgenic mice and in human tumors have established that epithelial cancers rely on multiple genetic abnormalities resulting in several aberrant signaling pathways that, in turn, mediate cancer maintenance and progression. Thus, because of the potential for compensation, it is anticipated that interruption of a single signaling network or transforming molecule will not be curative in , 2001) . The seminal studies with the HER2-blocking antibody Herceptin in patients with HER2-amplified metastatic breast cancer provide another example. Although some tumors regress with antibody therapy, the majority does not respond and/or eventually escape Herceptin action (Vogel et al., 2002) , supporting de novo as well as acquired mechanisms of therapeutic resistance. Similar to EGFR inhibitors, the antitumor effect of HER2 inhibitors would require the subversion of key postreceptor signaling pathways and cell cycle/apoptosis regulatory molecules that mediate the transforming effects of HER2. These postreceptor pathways are shared with and receive simultaneous inputs from heterologous receptor networks (Carpenter, 1999; Gschwind et al., 2001) . Indeed, overexpression of the IGF-I receptor has been reported to abrogate the antitumor effect of Herceptin as well as EGFR tyrosine kinase inhibitors against human tumor cells (Lu et al., 2001; Chakravarti et al., 2002) . In these studies, simultaneous blockade of either the IGF-I receptor or PI3K restored sensitivity to the HER2 and EGFR inhibitor, respectively. Taken together, these data suggest that tumor cells may be endowed with multiple signaling molecules that could potentially counteract the blockade of HER2 or EGFR function at the transmembrane receptor level. Inhibition of EGFR and HER2 has been shown to inhibit PI3K and Akt kinase and their downstream targets in several tumor cell lines (Busse et al., 2000; Lane et al., 2000; Lenferink et al., 2001; Moasser et al., 2001; Moulder et al., 2001) . Forced expression of active Akt prevents the antitumor effect of Herceptin against HER2-overexpressing SKBR-3 and BT-474 human breast cancer cells , suggesting that (1) inhibition of PI3K and Akt might be an obligate step for the cell cycle arrest and/or apoptosis mediated by HER2 inhibitors, and (2) abnormal hyperactivation of Akt can counteract the cellular effects of HER2 inhibitors. We speculate that the same should apply to EGFR inhibitors as well. One mechanism for aberrant activation of Akt is loss of PTEN, a phosphatase that negatively regulates PI3K and Akt by dephosphorylating PI3, 4, 5P3 (Cantley and Neel, 1999; Simpson and Parsons, 2001 ). Surveys of several tumors for PTEN gene deletion or mutations have shown PTEN loss in a wide spectrum of human cancers (Ali et al., 1999; Vivanco and Sawyers, 2002) . Although mutations of PTEN occur in o5% of breast cancers, some reports suggest severe loss of PTEN protein in breast tumors and frequent hemizygous deletions of the PTEN gene (Teng et al., 1997; Perren et al., 1999) . Therefore, we have examined the effects of the EGFR tyrosine kinase Submicromolar concentrations of ZD1839 markedly inhibited the growth of A431 but not PTEN-null MDA-468 cells. Of note, at concentrations that did not inhibit MDA-468 cell growth, ZD1839 induced loss of EGFR phosphorylation, dissociation of EGFR from p85a, and inhibition of MAPK activity. Potentially, owing to the low level of HER3 in these cells, we were unable to detect HER3 protein in EGFR precipitates from MDA-468 cells, suggesting the possibility that (1) EGFRassociated HER3 levels are too low to be detected by immunoblot, and/or (2) in these cells, an unidentified adaptor molecule couples the EGFR to p85a. These possibilities will require additional investigation. Despite its ability to inhibit EGFR phosphorylation in MDA-468 cells, ZD1839 treatment did not inhibit P-Akt levels. This result suggests that (1) in MDA-468 cells, PI3K and Akt activities are the result of at least two inputs, EGFR autocrine signals and loss of PTEN, and (2) the lack of inhibition of PI3K and Akt contributes to the resistance to ZD1839.
To test these possibilities, we stably reconstituted PTEN in MDA-468 cells. Re-expression of PTEN resulted in a reduction in basal PI3K activity and PAkt levels but did not change total Akt and EGFR protein levels. However, it restored the ability of ZD1839 to inhibit active Akt as well as to induce nuclear localization of FKHRL1. Simultaneous with these biochemical responses, treatment of ZD1839 resulted in marked induction of apoptosis and a modest delay in cell cycle progression in PTEN-expressing but not PTEN-null MDA-468 cells. These results imply that re-expression of PTEN in EGFR-overexpressing cells restores the receptor dependence of PI3K and Akt activation. This difference in sensitivity to EGFR inhibitors was also seen with the EGFR antibody C225 and the small-molecule tyrosine kinase inhibitor OSI-774. Furthermore, the differential sensitivity to ZD1839 observed between A431 and MDA-468 cells and between MDA-468/vector and MDA-468 cells was also observed between PTEN-positive H1355 and PTEN-mutant H157 NSCLC cells.
There are several implications that can be derived from these data. For example, EGFR-overexpressing tumors with concomitant amplification(s) of PI3K-Akt signaling may benefit from the combined blockade of the EGFR and Akt kinases. In addition to loss of PTEN function, the possible mechanisms that will result in a high threshold of PI3K and Akt activity will include overexpression of PI3K isoforms (Shayesteh et al., 1999; Fry, 2001) , Akt isoforms (Bellacosa et al., 1995; Nakatani et al., 1999; Sun et al., 2001a, b) , the cytoplasmic tyrosine kinases like Src and BRK (reviewed in Fry, 2001) , and heterologous receptor networks like the IGF-I receptor (Yu and Rohan, 2000) . Whether subjects bearing EGFR-expressing cancers with aberrant PI3K-Akt activity are less responsive to EGFR inhibitors can be tested prospectively in current clinical trials with EGFR inhibitors. Secondly, as clinical responses have been reported in recent trials with EGFR inhibitors in patients with advanced metastatic cancers Ranson et al., 2002) , it is possible that those responses are limited to tumors without amplification of PI3K-Akt signaling and in which inhibition of the EGFR was sufficient to inhibit this postreceptor signaling pathway.
Materials and methods
Cell lines and kinase inhibitors
A431 and MDA-468 cancer cell lines were purchased from the American Type Culture Collection (Manassas, VA, USA) and maintained in Improved Minimal Essential Zinc Option Medium (IMEM, Life Technologies, Inc., Rockville, MD, USA) supplemented with 10% fetal calf serum (FCS), 100 U/ ml penicillin, and 100 mg/ml streptomycin. All NSCLC lines were provided by Freddy Kaye (NCI/Naval Medical Oncology, Bethesda, MD, USA) and maintained in DMEM/10% FCS (Life Technologies, Inc.) supplemented with penicillin and streptomycin (Brognard et al., 2001) . LY294002 was purchased from BIOMOL (Plymouth Meeting, PA, USA) and reconstituted in DMSO. ZD1839 (Iressa) was provided by Steven Averbuch (AstraZeneca Pharmaceuticals, Wilmington, DE, USA). OSI-774 (Tarceva) was a gift from Mark Sliwkowski (Genentech, Inc., South San Francisco, CA, USA). Both ZD1839 and OSI-774 were reconstituted in DMSO and stored as 10-mm stock solutions. C225 (Cetuximab) was provided by Dan Hicklin (Imclone Systems, Inc., New York, NY, USA).
Cell proliferation and apoptosis assays
Cells were seeded in full medium in 12-well plates at a density of 3 Â 10 4 cells/well in triplicate; ZD1839 or LY294002 were added the next day. Medium and inhibitors were replenished every other day until cells were harvested by trypsinization and counted with a Zeiss Coulter Counter (Beckman Coulter, Miami, FL, USA). To measure apoptosis, cells were seeded in full growth medium in 60-mm dishes at the density of 2 Â 10 5 cells/dish. The following day, the medium with or without ZD1839 or LY294002 was changed. Both adherent and floating cells were harvested and pooled 72 h later and subjected to TUNEL assay utilizing the Apo-BrdU assay kit (Phoenix Flow Systems, San Diego, CA, USA) according to the manufacturer's protocol. Detection and quantitation of FITCpositive (apoptotic) cells were done with a FACS/Calibur Flow Cytometer (Becton Dickinson, Mansfield, MA, USA).
Immunoblot analysis and immunoprecipitation
After washes with phosphate-buffered saline (PBS) on ice, cell monolayers were lysed in a buffer containing 20 mm Tris, pH 7.4, 150 mm NaCl, 1% Nonidet P-40, 20 mm NaF, 1 mm Na 3 VO 4 , 1 mm PMSF, 2 mg/ml aprotinin, and 2 mg/ml leupeptin. Equal amount of protein in whole-cell lysates (as measured by Bradford) were separated by 8% (for EGFR, HER3, p85, and P-Tyr) or 12% (for Akt and MAPK) SDS-PAGE and transferred to nitrocellulose membranes. Immunoblot analyses were performed as described previously (Moulder et al., 2001; Yakes et al., 2002) using the following antibodies: polyclonal EGFR Ab-12 (NeoMarkers, Freemont, CA, USA); polyclonal HER3 C-17 and monoclonal PTEN A2B1 (Santa Cruz Biotechnology, Santa Cruz, CA, USA); p85 and monoclonal P-Tyr (Upstate Biotechnology, Lake Placid, NY, USA); S473 P-Akt, total Akt, and total MAPK (New England BioLabs, Beverly, MA, USA); T202/Y204 P-MAPK (Promega Corp., Madison, WI, USA). Horseradish peroxidase-linked anti-rabbit or anti-mouse secondary antibodies were used as described and immunoreactive bands visualized by enhanced chemiluminescence (ECL; Roche Molecular Biochemicals, Indianapolis, IN, USA). For immunoprecipitation, 300 mg of protein from whole-cell lysates were incubated overnight at 41C with 3 mg of EGFR Ab-12 (Neomarkers); protein A-Sepharose (Sigma, St Louis, MO, USA) was then added for 2 h while rocking. The precipitates were washed four times with ice-cold PBS, resuspended in Â 6 Laemmli buffer, and resolved by SDS-PAGE followed by Western blot analysis.
Retroviral infection
WT-PTEN was subcloned into the pBMN-IRES-EGFP retroviral vector (Grignani et al., 1998) (provided by Gary Nolan, Stanford University). 293 Phoenix amphitropic retrovirus-packaging cells (ATCC), expressing gag-pol and envelope proteins, were plated in a 60-mm dish at the density of 2.5 Â 10 6 cells/dish. After transfection of 3 mg pBMN-IRES-EGFP (vector control) or pBMN-PTEN-IRES-EGFP for 24 h using FUGENE 6 (Roche Molecular Biochemicals), virus was obtained by allowing the producing cells to reach confluence, removing the medium, and replacing it with half-volume of fresh serum-free medium. The conditioned medium was collected 48-72 h later and passed through a 45-mm filter. MDA-468 cells (5 Â 10 5 ) were plated on a 100-mm dish in IMEM/10% FCS. The following day, the medium was removed and replaced with 3 ml of a cocktail containing the retroviral supernatant (at an MOI of 80 plaque-forming units/ cell), 4 mg/ml polybrene, and IMEM/10% FCS. After 6 h, the medium was changed with fresh medium and the cells collected 48 h later. GFP-positive cells were sorted by flow cytometry and expanded in full medium. PTEN expression was confirmed by immunoblot analysis.
Phosphatidylinositol-3 kinase in vivo assay
Approximately 2 Â 10 5 MDA-468/vector and MDA-468/ PTEN cells/well were plated into six-well plates. The following day, cells were labeled for 16 h with 100 mCi/ml of 32 Porthophosphate (sp. act. 10 mCi/ml; Amersham, Piscataway, NJ, USA) on phosphate-free DMEM with 1 mm ZD1839 or 20 mm LY294002. Lipids were then extracted from the labeled cells and 32 P-labeled phospholipids analysed by thin-layer chromatography (TLC) as described previously [Chan, 2002 #533] . The intensity of the 32 P-IP3, 4, 5P3 band was quantitated using Image Gauge (version 4.0, Fuji) and expressed as a percentage relative to untreated cells.
FKHRL1 transfections and immunofluorescence
An expression vector encoding WT HA-tagged FKHRL1 was provided by Anne Brunet (Harvard Medical School, Boston, MA, USA). Cells were grown in 60-mm dishes (10 6 cells/dish) and then transfected with 10 mg HA-FKHRL1 for 16 h using FUGENE 6 (Roche). Cells were transferred to coverslips on 12-well plates, incubated with 1 mm ZD1839 for 24 h, and then subjected to immunostaining with anti-HA fluorescein (1 : 500; Roche) as described (Shin et al., 2001) . For detection of nuclei, cells were incubated with 1 mg/ml Hoechst 33258 (Sigma) after incubation with secondary antibody. Coverslips were mounted on glass slides with AquaPolyMount (Polysciences, Warrington, PA, USA) and examined by laser scanning confocal microscopy (Carl Zeiss LSM410).
Transcriptional reporter assays
Cells were seeded at a density of 10 5 cells/well in 12-well plates. On the following day, the cells were transfected with 0.5 mg/ well of FHRE-Luciferase (provided by Anne Brunet) and 0.005 mg pCMV-R1 (Promega) for 16 h with the use of FUGENE 6. Transfected cells were treated or not treated with 1 mm ZD1839 for 24 h. Firefly and Renilla reniformis luciferase activities in cell lysates were determined with the Dual Luciferase Assay System (Promega) in a Monolight 2001 luminometer (Analytical Luminescence Laboratory) as described previously (Shin et al., 2001) . Firefly luciferase activity was normalized to Renilla reniformis luciferase activity.
Cell cycle analysis
Cells were harvested by trypsinization, fixed in ethanol, and labeled with 50 mg/ml propidium iodide (Sigma) containing 125 U/ml protease-free RNAse (Calbiochem) as described previously (Busse et al., 2000) . Cells were filtered through a 95-mm pore size nylon mesh (Small Parts, Inc., Miami Lakes, FL, USA). A total of 15 000 labeled nuclei were analysed in a FACS/Calibur Flow Cytometer (Becton Dickinson).
Flow cytometry of cell surface EGFR
EGFR levels in H157 and H1355 cells were estimated by flow cytometry using the 528 EGFR monoclonal antibody (Santa Cruz Biotechnology) and a nonspecific IgG 2a (Sigma) following a previously described protocol (Moulder, 2001) .
